It stimulates insulin release from the beta cells of the pancreas
Dulaglutides safety profile is consistent with other GLP-1 receptor agonists, with transient nausea being the most frequently reported adverse event (14.6% incidence). Dose escalation from 0.75 to 1.5 mg is recommended after at least four weeks, based on individual glycemic control needs [57]
Lose Mode, which provides members with a consistent foundation for steady, sustainable progress
PMID: 26059826
The Tirzepatide Weight Loss Program is a clinician-guided telehealth program built around compounded tirzepatide, a dual-action medication that works on two metabolic pathways (GIP and GLP-1) to reduce appetite, quiet food noise, and support blood sugar balance
Select your format, set your goals, and book a time